RedChip Issues Research Profile on AV Therapeutics

Feb. 23, 2015 7:30 am |  More About AV Therapeutics

ORLANDO, Fla., Feb. 23, 2015 (GLOBE NEWSWIRE) -- RedChip Companies, Inc., today announced it has issued a research profile on AV Therapeutics, Inc. (OTCQB:AVTH), a developer of cancer therapeutics and vaccines.

Highlights of the report include:

Capridine-β uniquely exhibits prostate cancer (PCa) specificity, distinguishing it from currently available prostate cancer treatments. In preclinical studies, Capridine has shown an ability to specifically target prostate cancer cells, allowing it to home in and attack prostate cancer at the source.

Capridine-β showed a pronounced anti-tumor effect in DU-145 (prostate cancer cell line with moderate metastatic potential) cells. The graph below demonstrates the effects of varying doses of Capridine-β at different time intervals. As demonstrated, the percentage of cancer cells that survive decreases significantly as the time variable increases while there is a plateau effect dependent on the dose administered. This indicates that a low amount of the drug leads to high efficacy.

Low bone marrow toxicity improves odds of success, and could make it more amenable for various stages of prostate cancer. In preclinical studies, Capridine-β has shown very low bone marrow toxicities. This is crucial for a few reasons. This is another indicator that Capridine-β is a very targeted therapy, as seen by its strong specificity for PCa cells. Additionally, this indicates that the therapy is safer than other agents currently being used on the market. We believe that this could make Capridine-β eligible for use in multiple stages of prostate cancer care (stages 2-4) either as a standalone therapy or in conjunction with other treatments (likely in earlier stages; this could also help prevent resistance to other treatments).

Successful completion of GMP synthesis of Capridine-β; expected to commence phase I clinical trials in 1Q16. AVTH recently completed GMP synthesis of Capridine-β, with the product showing 99.8% purity and great conformity. This GMP product was used to create a limited toxicity profile, which is currently being analyzed by AVTH.

AVTH is expected to begin phase I clinical trials in 2015, following the completion of preclinical studies and an IND application. Following completion of the toxicology profile, AVTH estimates needing $750,000 to enter phase I clinical trials, along with an additional $1.5 million for phase I/II trials.

To receive a complimentary copy of the full RedChip Research Report for AVTH, please visit:

About RedChip Companies, Inc.

RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida; with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research™, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, Virtual Conferences, "The RedChip Money Report: Small Stocks Big Money"™ television show, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media and Blogging Services, and Webcasts. To learn more about RedChip's products and services, please visit:

"Discovering Tomorrow's Blue Chips Today"™


Advanced Vaccine Therapeutics has engaged RedChip Companies, Inc. to provide IR representation and consulting services.The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information). Investors are expected to take full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. Investors are further cautioned that small-cap and microcap stocks have additional risks that may result in trading at a discount to their peers. Liquidity risk, caused by small trading floats and very low trading volume can lead to large spreads and high volatility in stock price. Small-cap and microcap stocks may also have significant company-specific risks that contribute to lower valuations. Investors need to be aware of the higher probability of financial default and higher degree of financial distress inherent in the small-cap and microcap segments of the market. The information, opinions, data, quantitative and qualitative statements contained herein have been obtained from sources believed to be reliable but have not been independently verified and are not guaranteed as to accuracy, nor does it purport to be a complete analysis of every material fact regarding the company, industry, or security. The information, opinions, or recommendations are solely for advisory and informational purposes and are only valid as of the date appearing on the report and are subject to change without notice. Statements that are not historical facts are "forward-looking statements" that involve risks and uncertainties. "Forward looking statements" as defined under Section 27A of the Securities Act of 1933, Section 21B of the Securities Exchange Act of 1934 and the Private Securities Litigation Act of 1995 include words such as "opportunities," "trends," "potential," "estimates," "may," "will," "could," "should," "anticipates," "expects" or comparable terminology or by discussions of strategy. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of the company's or our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. Investors should consider these factors in evaluating the forward looking statements contained herein and not place undue reliance upon such statements. Investors are encouraged to read investment information available at the websites of the SEC at and FINRA at AV Therapeutics, Inc. ("AVTH") is a client of RedChip Companies, Inc. AVTH agreed to pay RedChip Companies, Inc., 864,000 shares of Rule 144 (restricted stock) and a monthly cash fee for RedChip consulting services and IR representation. Investor representation services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor representation services include the preparation of a research profile(s), multimedia marketing, and other awareness services.

CONTACT: Jon Cunningham
         RedChip Companies Inc.
         800-733-2447 Ext. 107

RedChip Companies Inc. Logo

February 23, 2015 - 7:30 AM EST

comments powered by Disqus

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market